Multi-Center, Parallel-Group, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Safety and Efficacy of Oral Lubiprostone in Patients with Chronic Idiopathic Constipatio
Phase 2
- Conditions
- Chronic Idiopathic Constipation
- Registration Number
- JPRN-jRCT2080220460
- Lead Sponsor
- Sucampo Pharma, Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Adult chronic idiopathic constipation
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy, Safety
- Secondary Outcome Measures
Name Time Method